<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647708</url>
  </required_header>
  <id_info>
    <org_study_id>MS200569_0004</org_study_id>
    <secondary_id>2020-003118-11</secondary_id>
    <nct_id>NCT04647708</nct_id>
  </id_info>
  <brief_title>Study of M5049 in CLE and SLE Participants</brief_title>
  <official_title>A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in SLE and CLE Participants Treated With Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally&#xD;
      administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus&#xD;
      erythematosus (CLE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">March 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Cohort 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Event of Special Interest (AESI), TEAEs Leading to Permanent Treatment Discontinuation and Treatment-Related TEAEs</measure>
    <time_frame>Up to Day 102</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Event of Special Interest (AESI), TEAEs Leading to Permanent Treatment Discontinuation and Treatment-Related TEAEs</measure>
    <time_frame>Up to Day 186</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Based on Severity</measure>
    <time_frame>Up to Day 102</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Based on Severity</measure>
    <time_frame>Up to Day 186</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 1 and 2: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters, Vital Signs, Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to Day 102</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters, Vital Signs, Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to Day 186</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 1 and 2: Number of Participants with Confirmed Signs and Symptoms of Prodromal Seizure</measure>
    <time_frame>Up to Day 102</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Confirmed Signs and Symptoms of Prodromal Seizure</measure>
    <time_frame>Up to Day 186</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cohort 1 and 2: Number of Participants with Suicidal Behavior and Suicidal Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to Day 102</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of M5049</measure>
    <time_frame>Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Time to Reach Maximum Plasma Concentration (tmax) of M5049</measure>
    <time_frame>Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of M5049</measure>
    <time_frame>Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M5049</measure>
    <time_frame>Day 1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc Cmax) of M5049</measure>
    <time_frame>Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Elimination Rate Constant (Lambda z) of M5049</measure>
    <time_frame>Day 1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Apparent Terminal Half-life (t1/2) of M5049</measure>
    <time_frame>Day 1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to 12 Hours Post-Dose (AUC0-12h) of M5049</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Dose Normalized Area Under Plasma Concentration-Time Curve from Time Zero to 12 Hours Post-Dose (AUC0-12h/Dose) of M5049</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Total Body Clearance (CL/f) of M5049</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Apparent Volume of Distribution (Vz/f) of M5049</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of M5049</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Dose Normalized Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf/Dose) of M5049</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Activity Index (CLASI-A)</measure>
    <time_frame>Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Change from Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)</measure>
    <time_frame>Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Change from Baseline in 28-Joint Count</measure>
    <time_frame>Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Change from Baseline in Physician Global Assessment (PGA) Score</measure>
    <time_frame>Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Cutaneous Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Part A (Cohort 1): M5049 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (Cohort 2): M5049 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (Cohort 3): M5049 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (Cohort 4): M5049 Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Cohort 5): M5049 Dose E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive low oral dose of M5049, twice daily in Part A.</description>
    <arm_group_label>Part A (Cohort 1): M5049 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive ascending oral dose of M5049, twice daily in Part A.</description>
    <arm_group_label>Part A (Cohort 2): M5049 Dose B</arm_group_label>
    <arm_group_label>Part A (Cohort 3): M5049 Dose C</arm_group_label>
    <arm_group_label>Part A (Cohort 4): M5049 Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive high oral dose of M5049, twice daily in Part B.</description>
    <arm_group_label>Part B (Cohort 5): M5049 Dose E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to M5049.</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active systemic lupus erythematosus (SLE) with a Cutaneous lupus erythematosus disease&#xD;
             area and activity index (CLASI-A) greater than or equal to [&gt;= ] 6 and/or at least one&#xD;
             active SLE clinical manifestation according to Systemic Lupus Erythematosus Disease&#xD;
             Activity Index 2000 (SLEDAI-2K)&#xD;
&#xD;
          -  Active cutaneous lupus erythematosus (CLE) (subacute cutaneous lupus erythematosus&#xD;
             and/or discoid lupus erythematosus) with a CLASI-A &gt;= 6&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autoimmune or rheumatic disease other than SLE or CLE&#xD;
&#xD;
          -  Dermatological diseases other than cutaneous manifestations of SLE or CLE&#xD;
&#xD;
          -  Uncontrolled medical conditions including significant cardiovascular events, active&#xD;
             lupus nephritis, and active neurological disorder&#xD;
&#xD;
          -  Ongoing or active clinically significant viral, bacterial or fungal infection&#xD;
&#xD;
          -  History of uncontrolled seizures or other neurological disorder&#xD;
&#xD;
          -  History of or positive for human immunodeficiency virus, hepatitis C virus, or&#xD;
             hepatitis B virus&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical center Medconsult Pleven OOD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinski Zentar-1-Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy - MHAT - Sofia</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMBAL Sv. Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski EAD Clinic of Rheumatology&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fraunhofer Institute for Molecular Biology and Applied Ecology IME</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Phase I Unit, Clinical Republican Hospital</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company &quot;Harmoniya krasy&quot;, Department of clinical trials</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200569_0004</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus Erythematosus, Systemic</keyword>
  <keyword>Lupus Erythematosus, Cutaneous</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

